Neos Therapeutics (NEOS) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neos Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results
March 17, 2016 7:00 AM EDTLaunch of Adzenys XR-ODT in Second Quarter of 2016
Company to Host Conference Call at 8:30am ET Today
DALLAS/FORT WORTH, Texas, March 17, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced financial results for the fourth quarter and 2015 fiscal year ended December 31, 2015.
The past fifteen months have been incredibly exciting for Neos Therapeutics as we have... More
